Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
09/27/2012
Trade Name:
QUILLIVANT XR
Generic Name or Proper Name (*):
methylphenidate hydrochloride
Indications Studied:
Treatment of Attention Deficit Hyperactivity Disorder
Label Changes Summary:
Safety and effectiveness have been established in pediatric patients ages 6 - 17 years Use in pediatric patients 6 - 12 years of age is supported by adequate and well-controlled studies. Use in 12 - 17 year olds is supported by the adequate and well-controlled studies of Quillivant XR in younger pediatric patients and additional pharmacokinetic data in adolescents, with safety information from other methylphenidate products The long-term efficacy of methylphenidate in pediatric patients has not been established Safety and efficacy in pediatric patients below the age of 6 years have not been established Growth should be monitored during treatment with stimulants, including Quillivant XR. Children who are not growing or gaining weight as expected may need to have their treatment interrupted Information on adverse reactions, pharmacokinetics and clinical tria lNew dosage form
Product Labeling:
Labeling
PREA(P):
P
Sponsor:
NextWave Pharmaceuticals, Inc.
NNPS:
FALSE'
Therapeutic Category:
CNS Stimulant
-
-